REG - Scancell Hlds - Directorate Change

Scancell HoldingsAnnouncement

05/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240205:nRSE9423Ba&default-theme=true

RNS Number : 9423B  Scancell Holdings Plc  05 February 2024

5 February 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

 

Directorate Change and Appointment of Head of Development

 

·      Dr Sally Adams to retire as an Executive Director of the Board
and as Chief Development Officer

·      Dr Callum Scott has been appointed as Head of Development

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, today announces that Dr Sally
Adams is retiring as an Executive Director of the Board and as Chief
Development Officer. Dr Callum Scott has been appointed as the new Head of
Development, effective immediately, and Sally will remain with the Company
part time for 6 months to ensure a smooth and effective transition of
responsibilities.

 

Dr Scott brings over 15 years of experience in vaccine research and
development. Previously, he held the role of Technical Transfer &
Formulation Development Manager at UK biotech firm Allergy Therapeutics (AIM:
AGY) where he led all CMC (Chemistry, Manufacturing and Controls)/product
development activities relating to their VLP Peanut project through Phases 1-3
including IND approvals. Dr Scott holds a PhD in Molecular Microbiology and a
BSc in Biochemistry, both from Heriot-Watt University.

 

Prof Lindy Durrant, Chief Executive Officer of Scancell, commented: "Firstly,
on behalf of the Scancell Board, I would like to express our sincere gratitude
to Sally for her expertise and support over the last 15 years, both on the
Board and leading clinical development. She has been instrumental in
establishing a highly motivated development team and has worked tirelessly to
bring our highly differentiated and valuable cancer vaccines through to the
clinic. We wish her all the best for the future.

 

"I would also like to warmly welcome Callum to Scancell. His understanding of
the challenges involved in developing, registering, and commercialising novel
biologics will be of great value to Scancell as we continue to develop our
lead assets SCIB1 and Modi-1 through later stage clinical development."

 

Dr Sally Adams, Chief Development Officer, said: "It has been a privilege to
work with Lindy and the Scancell team for the last 15 years, helping to
develop successful manufacturing processes and quality systems and to take
three products into the clinic. The recent clinical successes with SCIB1 and
Modi-1 have been the culmination of a huge team effort across the Company, and
I have every confidence that these results will be built upon in the future. I
wish Lindy and the Company every success."

 

Dr Callum Scott, Head of Development, commented: "Joining Scancell when SCIB1
and Modi-1 cancer vaccines are making highly promising clinical progress is
very exciting, with further data from the SCOPE study expected in mid-2024 and
ModiFY trial later this year. I look forward to contributing to the rapid
advancement of these innovative and high-value assets through the clinic and
towards commercialisation and working with Lindy and the Scancell team."

 

 For further information, please contact:

 Scancell Holdings plc                                                        +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment
 Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                               +44 (0) 20 3705 9330

 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                                   +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 ICR Consilium                                                                +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh                                   scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUSSNRSKUURAR